human factor ix
human factor ix structure
|
Common Name | human factor ix | ||
|---|---|---|---|---|
| CAS Number | 9001-28-9 | Molecular Weight | 283.277 | |
| Density | 1.3±0.1 g/cm3 | Boiling Point | 471.1±45.0 °C at 760 mmHg | |
| Molecular Formula | C13H17NO6 | Melting Point | N/A | |
| MSDS | USA | Flash Point | 238.7±28.7 °C | |
|
Mechanism of hypocoagulability in proton-irradiated ferrets.
Int. J. Radiat. Biol. 89(10) , 823-31, (2013) To determine the mechanism of proton radiation- induced coagulopathy.Ferrets were exposed to either solar particle event (SPE)-like proton radiation at a predetermined dose rate of 0.5 Gray (Gy) per hour (h) for a total dose of 0 or 1 Gy. Blood was collected ... |
|
|
Hepatocyte clearance and pharmacokinetics of recombinant factor IX glycosylation variants.
Biochem. Biophys. Res. Commun. 440(4) , 485-9, (2013) Addition of N-linked glycosylation sites has been shown to increase serum half-life and decrease clearance for proteins such as recombinant erythropoietin (EPO). However, factor IX (FIX) variants with additional N-linked glycans ("HG" variants) that were expr... |
|
|
Genetic sequence analysis of inherited bleeding diseases.
Blood 122(20) , 3423-31, (2013) The genes encoding the coagulation factor proteins were among the first human genes to be characterized over 25 years ago. Since then, significant progress has been made in the translational application of this information for the 2 commonest severe inherited... |
|
|
Development of long-acting recombinant FVIII and FIX Fc fusion proteins for the management of hemophilia.
Expert Opin. Biol. Ther. 13(9) , 1287-97, (2013) Prophylactic treatment with replacement clotting factor is the recommended regimen for patients with severe hemophilia to prevent bleeding episodes. However, currently available replacement clotting factors are limited by their relatively short half-lives and... |
|
|
The Canadian "National Program for hemophilia mutation testing" database: a ten-year review.
Am. J. Hematol. 88(12) , 1030-4, (2013) A reference genotyping laboratory was established in 2000 at Queen's University, Kingston, to provide genetic testing for Hemophilia A (HA) and B (HB) and create a Canadian mutation database. Canadian hemophilia treatment centers and genetics clinics provided... |
|
|
Females with FVIII and FIX deficiency have reduced joint range of motion.
Am. J. Hematol. 89(8) , 831-6, (2014) Little is known about rates of joint bleeding among females with FVIII/FIX deficiency or hemophilia carriers. In a cross-sectional study, we tested the hypothesis that females with FVIII or FIX deficiency enrolled in the Universal Data Collection (UDC) projec... |
|
|
Issues in pediatric haemophilia care.
Ital. J. Pediatr. 39 , 24, (2013) The hemophilias are the most common X-linked inherited bleeding disorders. The challenges in children are different from that in adults and, If not properly managed, can lead to chronic disease and lifelong disabilities. Currently, inhibitors are the most sev... |
|
|
A principal component analysis of coagulation after trauma.
J. Trauma Acute Care Surg. 74(5) , 1223-9; discussion 1229-30, (2013) Clotting factor abnormalities underlying acute traumatic coagulopathy are poorly understood, with application of traditional regression techniques confounded by colinearity. We hypothesized that principal components analysis (PCA), a pattern-finding and data ... |
|
|
Inhibitor eradication with rituximab in haemophilia: where do we stand?
Br. J. Haematol. 165(5) , 600-8, (2014) Rituximab is a humanized chimeric anti-CD20 monoclonal antibody initially developed for the treatment of some haematological malignancies. Thanks to its ability to rapidly and specifically deplete B cells, it has also been used in a variety of autoimmune diso... |
|
|
Haemophilia part 1: an introduction.
Br. J. Nurs. 22(11) , 620, (2013)
|